-
Adamas Pharma's Gocovri Approved, A Welcome Addition To Parkinson's Treatments
Friday, August 25, 2017 - 12:03pm | 695Read More...Adamas Pharmaceuticals Inc (NASDAQ: ADMS) shares were on a tear Friday following that the FDA has approved its GOCOVRI extended release capsules for dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without dopaminergic medications. At the time of...
-
Janney Upgrades Amicus, Says EU Approval 'Likely'
Tuesday, March 8, 2016 - 10:09am | 257Read More...Janney’s Roy Buchanan upgraded the rating for Amicus Therapeutics, Inc. (NASDAQ: FOLD) from Neutral to Buy, while raising the fair value estimate from $10 to $12. He said that although there was uncertainty regarding the FDA’s decision on migalastat in Fabry’s, a CHMP opinion...
-
Janney: Time To Buy Acceleron
Monday, February 29, 2016 - 1:52pm | 315Read More...On Monday, Janney issued a company note on Acceleron Pharma Inc (NASDAQ: XLRN) after the company announced positive Phase III trial results of their drug that treats metastatic renal cell carcinoma (mRCC). Analysts at Janney upgraded Acceleron from Neutral to Buy, while lowering their price target...
-
Janney Analyst Starts Clovis Oncology At Buy, Expects Regulatory Approvals Coming In 2016
Thursday, December 17, 2015 - 10:51am | 292Read More...The share price of Clovis Oncology Inc (NASDAQ: CLVS) has appreciated 7.57 percent in the last month, after having fallen 70.08 percent over the past three months. Janney’s Roy Buchanan has initiated coverage of the company with a Buy rating and fair value of $50. Buchanan expects...
